J&J's Next Immunology Act Centers On Nipocalimab For Autoantibody-Driven Diseases

 
• By Jessica Merrill

The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.

pillar
J&J outlined a broad development plan for nipocalimab, which it hopes will be a new pillar brand • Source: Alamy

More from Immunological

More from Therapy Areas